Suppr超能文献

分泌催乳素的垂体微腺瘤:多巴胺激动剂药物治疗后经蝶窦手术的结果

Prolactin Secreting Pituitary Microadenoma: Results of Transsphenoidal Surgery After Medical Therapy With Dopamine Agonist.

作者信息

Fraioli Mario Francesco, Umana Giuseppe, Pagano Andrea, Fraioli Bernardo, Lunardi Pierpaolo

机构信息

*Department of Neurosciences, Neurosurgery, University of Rome Tor Vergata †Department of Diagnostic for Imaging and Radiotherapy, CIRAD of Rome, Rome, Italy.

出版信息

J Craniofac Surg. 2017 Jun;28(4):992-994. doi: 10.1097/SCS.0000000000003663.

Abstract

Medical therapy with dopamine agonist is very effective in controlling prolactin serum levels and it usually represents the first therapeutic choice for prolactin secreting pituitary adenomas. However, many patients present increase of prolactinemia after withdrawal of medical therapy which consequently should be taken for long time; other present intolerance to medical therapy; women with pregnancy need to withdraw dopamine agonists with consequent potential related problems: in these patients transsphenoidal surgery can be requested. The presented study concerns the efficacy of transsphenoidal surgery in patients affected by microprolactinoma after treatment with medical therapy for different periods of time. Different postsurgical results were achieved in 2 groups of 24 (group 1) and 25 (group 2) patients affected by microprolactinoma who had taken medical therapy for a period of time respectively longer or shorter than 1 year. In summary, the authors observed in group 1 a rate of hormonal remission of 33.3% and an overall prolactinemia improvement with possibility of medical therapy withdrawal in 49.9% of patients. In group 2, the authors observed a rate of hormonal remission of 84% and an overall rate of improvement with no necessity of medical therapy of 92%. Therefore, the authors' experience showed that the surgical option for the therapy of microprolactinomas should be indicated within 1 year from the beginning of medical therapy with dopamine agonist, to achieve a high rate of hormonal remission and possibility to withdraw medical therapy. The authors' protocol for microprolactinoma treatment is presented.

摘要

使用多巴胺激动剂进行药物治疗在控制血清催乳素水平方面非常有效,它通常是分泌催乳素的垂体腺瘤的首选治疗方法。然而,许多患者在停药后会出现催乳素血症升高,因此需要长期服药;其他患者对药物治疗不耐受;怀孕的女性需要停用多巴胺激动剂,从而可能引发相关问题:在这些患者中,可以考虑经蝶窦手术。本研究关注经蝶窦手术对接受不同时间段药物治疗的微泌乳素瘤患者的疗效。分别对两组微泌乳素瘤患者进行经蝶窦手术,其中一组24例(第1组),另一组25例(第2组),他们接受药物治疗的时间分别长于或短于1年,术后取得了不同的结果。总之,作者在第1组中观察到激素缓解率为33.3%,49.9%的患者总体催乳素血症得到改善,且有可能停药。在第2组中,作者观察到激素缓解率为84%,92%的患者总体得到改善,无需药物治疗。因此,作者的经验表明,对于微泌乳素瘤的治疗,手术选择应在开始使用多巴胺激动剂进行药物治疗的1年内进行,以实现高激素缓解率和停药的可能性。本文还介绍了作者治疗微泌乳素瘤的方案。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验